Cebo Do you know what price Jupiter started their short ? if it was in the £2ish they have made a lot of money but as you said let’s hope they get caught in the squeeze.
RNS informing partnership with Tufts click on the link from 3 years ago look at share price then. £1.06 same as today now I know this is over sold and dirt cheap.
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has agreed a co-development partnership with Bach BioSciences, a company commercialising the research of William Bachovchin, Professor of Developmental, Chemical and Molecular Biology at Tufts University School of Medicine, Boston.
Templar I didn’t know Avacta were using patients who have nothing else to try.(Last throw of the dice for these brave patients.) in this trial. I hope just for their sakes AVA6K works and we see some positive news for these patients. Ranting for other news ain’t going to receive much sympathy on here.
AS & NB didn’t have to do the interview but they did and it was very informative.
Oncology Oncologists diagnose and treat cancers of all types. They use diagnostic tools like biopsies, endoscopies, X-ray and other imaging, nuclear medicine, and blood tests. Cancer surgeons, or surgical oncologists, remove tumors, while medical oncologists treat cancers with chemotherapy. Radiation oncologists use multiple forms of radiation in an effort to eliminate tumors.
Example: Velcade • Bortezomib (Velcade, Takeda Pharmaceuticals) had annual sales of $1.2bn (2018) • BUT – approval limited to multiple myeloma because of dose limiting toxicities, • AND - coming off patent by 2022.
News Flash from Yorkshire Avacta’s board are all trapped in a pot hole cave just outside Wetherby.
Team building exercise goes horribly wrong. Big Al took the whole board down the cave for a team building exercise to see if they could survive for 5 working days in the dark. Big Al explained to his board we need to connect with our PI’s and see what it is like for 5 days in the dark while the stock market is open.
Just as they where preparing to climb back to the surface there was a mud slide with all the recent rain and they all become trapped. Big Al refused to allow mobiles on the exercise so none of the board could cheat,so they were well and truly stuck.
Just when they thought they were all doomed,Big Al started to search for water in the dark and moved a rock, he saw a flash of light down a hole reached down and it was a burner phone with £20 credit and one Chinese phone number.
So he phoned the number and a team of Chinese rescuers are on their way to free them.
The head of the Chinese rescuers said stay calm Jim we will have you and Matt out soon.
So now everyone knows where the famous burner phone was stashed………
For the kids in the back of the car.17 Aug 2021 13:02
Well it nearly a year since Vaccine Gate. Avacta crashed,AS share sale and the trolls took control. At the time we were all waiting on Saliva test, Bams, and Moonshot.
We went through the run up to Christmas in lockdown then a bit of good news, licence agreement with Astrea Bioseparations. New Year and a license agreement with Point Biopharma. February Started well Affyxell agreement then Mologic agreement followed by initial evaluation of Affidx followed by AVA6000 trial approval. March Brought the Business update and Biokit deal. April Things started to hot up deal with Abcam then Clinical validation of AffiDX. May Change of advisor and CE submission. June CE confirmed with MHRA and EU. July ISO 13485 August Affidx sales start and AVA6000 first dose in trial.
Now we are at “Are we there yet Gate” Trolls complaining no news,new investors spooked and selling.
Look back at the last year we have had good news in every month since December 2020 and the biggest news is still to come.
This is just my opinion but Medusa haven’t spent all those millions on setting up a diagnostic manufacturing and distribution company for one test that could be phased out in a few years time.They are here to stays down they know how to sell to the public.The Affidx pipeline is what they are looking at. Affimers in Diagnostic tests now proven with advantages of size, stability, versatility, rapid development and ease of production. So a sale of this side of the business is on the cards. Could be Medusa or even a big player like Bruker of ThermoFisher. Once AVA6K completes phase 1 the Therapeutic side of the business could be heading to the Nasdaq were it will achieve the valuation it deserves.
So long, farewell, auf Wiedersehen, good night I hate to go and leave this pretty sight So long, farewell, auf Wiedersehen, adieu Adieu, adieu, to yieu and yieu and yieu So long, farewell, au revoir, auf wiedersehen
RE: AVA 6000 - Chance of commercialsiation = High11 Aug 2021 11:23
Any small reduction in side effects and it’s a winner Cost to patients on side effects a lot of stress and suffering. Cost to NHS billions saved on anti chemo drugs.